טוען...
Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines
Doxorubicin plays an integral role in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) but can be associated with significant toxicity. Treatment guidelines of British Columbia (BC) Cancer recommend the substitution of etoposide for doxorubicin in standard-dose R-CHOP (rituximab,...
שמור ב:
| הוצא לאור ב: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Hematology
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7948286/ https://ncbi.nlm.nih.gov/pubmed/33683338 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002982 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|